DrugPatentWatch Database Preview
CEFTIN Drug Profile
» See Plans and Pricing
Which patents cover Ceftin, and when can generic versions of Ceftin launch?
Ceftin is a drug marketed by Glaxosmithkline and is included in two NDAs.
The generic ingredient in CEFTIN is cefuroxime axetil. There are sixty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the cefuroxime axetil profile page.
US ANDA Litigation and Generic Entry Outlook for Ceftin
A generic version of CEFTIN was approved as cefuroxime axetil by APOTEX on October 2nd, 2002.
Summary for CEFTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Bulk Api Vendors: | 29 |
| Patent Applications: | 21 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CEFTIN |
| DailyMed Link: | CEFTIN at DailyMed |
US Patents and Regulatory Information for CEFTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | CEFTIN | cefuroxime axetil | FOR SUSPENSION;ORAL | 050672-001 | Jun 30, 1994 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Glaxosmithkline | CEFTIN | cefuroxime axetil | TABLET;ORAL | 050605-002 | Dec 28, 1987 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Glaxosmithkline | CEFTIN | cefuroxime axetil | FOR SUSPENSION;ORAL | 050672-002 | Apr 29, 1997 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
